Turbotodd

Ruminations on tech, the digital media, and some golf thrown in for good measure.

Archive for July 21st, 2017

Alexa, Buy Graphiq

leave a comment »

Amazon’s doing some shopping of its own, this week acquiring Santa Barbara-based data analytics and search engine startup Graphiq for an estimated $50M.

According to Crunchbase, Graphiq positioned itself as a data aggregation and visualization company focused on turning cmoplicated data into contextually-rich presentations of the world’s knowledge.

The company was founded in 2009 as “FindTheBest,” according to the LA Times, and was co-founded with former DoubleClick CEO and Founder, Kevin O’Connor.

How will Graphiq’s technology possibly be used in the Amazon?

The technology Graphiq has developed to connect the dots between billions of pieces of information could be valuable to Amazon as it tries to make Alexa smarter. Akin to Siri on the iPhone, Alexa answers queries about the weather, sports and other topics on devices such as Amazon’s Echo speaker. Last year, Graphiq produced a now-unavilable Alexa app that aimed to answer questions such as “What is the fastest 2016 sedan?” according to app aggregation website ChatBottle. Amazon also gave Graphiq access to a database about books to put its technology to the test, according to a source.
– via latimes.com

Written by turbotodd

July 21, 2017 at 10:41 am

IBM and University of Alberta Publish New Data on Machine Learning Algorithms to Help Predict Schizophrenia

leave a comment »

IBM scientists and the University of Alberta in Edmonton, Canada, have published new data in Nature’s partner journal, Schizophrenia1, demonstrating that AI and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy.

This retrospective analysis also showed the technology predicted the severity of specific symptoms in schizophrenia patients with significant correlation, based on correlations between activity observed across different regions of the brain. This pioneering research could also help scientists identify more reliable objective neuroimaging biomarkers that could be used to predict schizophrenia and its severity.

Schizophrenia is a chronic and debilitating neurological disorder that affects 7 or 8 out of every 1,000 people. Those with schizophrenia can experience hallucinations, delusions or thought disorders, along with cognitive impairments, such as an inability to pay attention and physical impairments, such as movement disorders.

“This unique, innovative multidisciplinary approach opens new insights and advances our understanding of the neurobiology of schizophrenia, which may help to improve the treatment and management of the disease,” says Dr. Serdar Dursun, a Professor of Psychiatry & Neuroscience with the University of Alberta. “We’ve discovered a number of significant abnormal connections in the brain that can be explored in future studies, and AI-created models bring us one step closer to finding objective neuroimaging-based patterns that are diagnostic and prognostic markers of schizophrenia.”

In the paper, researchers analyzed de-identified brain functional Magnetic Resonance Imaging (fMRI) data from the open data set, Function Biomedical Informatics Research Network (fBIRN) for patients with schizophrenia and schizoaffective disorders, as well as a healthy control group. fMRI measures brain activity through blood flow changes in particular areas of the brain.

Specifically, the fBIRN data set reflects research done on brain networks at different levels of resolution, from data gathered while study participants conducted a common auditory test. Examining scans from 95 participants, researchers used machine learning techniques to develop a model of schizophrenia that identifies the connections in the brain most associated with the illness.

The results of the IBM and University of Alberta research demonstrated that, even on more challenging neuroimaging data collected from multiple sites (different machines, across different groups of subjects etc.) the machine learning algorithm was able to discriminate between patients with schizophrenia and the control group with 74% accuracy using the correlations in activity across different areas of the brain. 

Additionally, the research showed that functional network connectivity could also help determine the severity of several symptoms after they have manifested in the patient, including inattentiveness, bizarre behavior and formal thought disorder, as well as alogia, (poverty of speech) and lack of motivation.

The prediction of symptom severity could lead to a more quantitative, measurement-based characterization of schizophrenia; viewing the disease on a spectrum, as opposed to a binary label of diagnosis or non-diagnosis. This objective, data-driven approach to severity analysis could eventually help clinicians identify treatment plans that are customized to the individual. 

“The ultimate goal of this research effort is to identify and develop objective, data-driven measures for characterizing mental states, and apply them to psychiatric and neurological disorders” said Ajay Royyuru, Vice President of Healthcare & Life Sciences, IBM Research. “We also hope to offer new insights into how AI and machine learning can be used to analyze psychiatric and neurological disorders to aid psychiatrists in their assessment and treatment of patients.”

The Research Domain Criteria (RDoC) initiative of NIMH emphasizes the importance of objective measurements in psychiatry. This field, often referred to as “computational psychiatry”, aims to use modern technology and data driven approaches to improve evidence-based medical decision making in psychiatry, a field that often relies upon subjective evaluation approaches.

As part of the ongoing partnership, researchers will continue to investigate areas and connections in the brain that hold significant links to schizophrenia. Work will continue on improving the algorithms by conducting machine learning analysis on larger datasets, and by exploring ways to extend these techniques to other psychiatric disorders such as depression or post-traumatic stress disorder.

You can learn more about IBM Watson Health solutions here.

Written by turbotodd

July 21, 2017 at 9:21 am

%d bloggers like this: